For those of you who think you're so hip and cool snorting ketamine, I've got news for you: That shit has its own patent now!
Javelin Pharmaceuticals said it has been granted a commercially important US patent, enabling protection of its intranasal ketamine drug candidates into 2023.
Fred Mermelstein, president and founder, said: "Upon approval, PMI-150 will be the only intranasal ketamine product offering physicians and patients a non-opioid alternative for treatment of moderate to severe pain. It will be well-suited for both civilian and military use in medically supervised settings."
Damn straight, yo! Snorting ketamine is now considered "Intellectual Property" until 2023, so remember to kick back a few bucks to Javelin Pharmaceuticals every time you blow a bump, and be sure to call it "PMI-150" instead of "Special K", that's the new slang, for real.
